Massive Clonidine Overdose During Refill of an Implanted Drug Delivery Device for Intrathecal Analgesia: A Review of Inadvertent Soft-Tissue Injection During Implantable Drug Delivery Device Refills and Its Management

Pain Medicine

Volumn 12, Issue 7, 2011, Pages 1032-1040

  Johnson, Marlene L ^a   Visser, Eric J ^b   Goucke, C Roger ^c,d  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Clonidine; Complications; Implantable Drug Delivery Device; Intrathecal Analgesia; Overdose; Subcutaneous Injection

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; MORPHINE; OMEGA CONOTOXIN MVIIA; OPIATE DERIVATIVE;

CHRONIC PAIN; DRUG DELIVERY SYSTEM; DRUG OVERDOSE; HEART FAILURE; HEART INFARCTION; HUMAN; RESUSCITATION; REVIEW; RISK ASSESSMENT; SOFT TISSUE; UNCONSCIOUSNESS;

EID: 79960346499     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01146.x     Document Type: Review

References (39)

1. Frye CB, Vance MA. Hypertensive crisis and myocardial infarction following massive clonidine overdose. Ann Pharmacother 2000;34(5):611-5.
2. Coyne PJ, Hansen LA, Laird J, Buster P, Smith TJ. Massive hydromorphone dose delivered subcutaneously instead of intrathecally: Guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. J Pain Symptom Manage 2004;28(3):273-6.
3. Safety Alert. Important Clinical Information about Pocket Fills. Australia: Medtronic Australasia Pty Ltd; 2011. Available at: (accessed January 2011).
4. Deer T, Krames ES, Hassenbusch SJ, etal. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007;10(4):300-28.
5. Staats PS. Complications of intrathecal therapy. Pain Med 2008;9(suppl 1):S102-7.
6. Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic non-cancer pain: A systematic review of effectiveness and complications. Clin J Pain 2007;23(2):180-95.
7. th Annual Scientific Meeting, Adelaide, 2007.
8. Shankar H. Ultrasound-guided localization of difficult-to-access refill port of the intrathecal IDDD reservoir. Neuromodulation 2009;12(3):215-8.
9. Medtronic Inc. Medtronic: Indications, drug stability, and emergency procedures; SynchroMed® and IsoMed® implantable infusion systems reference manual. USA (2009).
10. Krames E, Poree LR, Deer T, Levy R. Rethinking algorithms of pain care: The use of the S.A.F.E. principles. Pain Med 2009;10(1):1-5.
11. Atli A, Theodore BR, Turk DC, Loeser JD. Intrathecal opioid therapy for chronic non-malignant pain: A retrospective cohort study with 3-year follow-up. Pain Med 2010;11(7):1010-6.
12. Deer TR. A prospective analysis of intrathecal granuloma in chronic pain patients: A review of the literature and report of a surveillance study. Pain Physician 2004;7(2):225-8.
13. Royal MA, Wiesemeyer DL, Gordin V. Intrathecal opioid conversions: The importance of lipophilicity. Neuromodulation 1998;1(4):195-7.
14. Belmans L, Van Buyten JP, Vanduffel L. Accidental overdosing with intraspinal morphine caused by misprogrammation of a Synchromed IDDD: A report of two cases. Acta Anaesthesiol Belg 1997;48(2):93-7.
15. Groudine SB, Cresanti-Daknis C, Lumb PD. Successful treatment of a massive intrathecal morphine overdose. Anesthesiology 1995;82(1):292-5.
16. Sauter K, Kaufman HH, Bloomfield SM, Cline S, Banks D. Treatment of high-dose intrathecal morphine overdose. J Neurosurg 1994;81(1):143-6.
17. Coffey RJ, Owens ML, Broste SK, etal. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat non-cancer pain. Anesthesiology 2009;111(4):881-91.
18. Patel VB, Manchikanti L, Singh V, etal. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009;12(2):345-60.
19. Smith HS, Deer TR, Staats PS, etal. Intrathecal drug delivery. Pain Physician 2008;11(suppl 2):S89-104.
20. Van Hilten BJ, Van De Beek WT, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000;343(9):625-30.
21. Rauck RL, Eisenach JC, Jackson K, Young LD, Southern J. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology 1993;79(6):1163-9.
22. Tran DQH, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: A review of the evidence. Can J Anaesth 2010;57(2):149-66.
23. Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010;11(2):262-73.
24. 2-adrenergic agonists and antagonists in clinical practice: Background, facts and perspectives. Curr Top Med Chem 2007;7(2):187-94.
25. Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: Implications of increased prescribing. J Paediatr Child Health 1998;34(6):508-12.
26. Seger D. Clonidine toxicity revisited. Clin Toxicol 2002;40(2):145-55.
27. Domino LE, Domino SE, Stockstill MS. Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose. Br J Clin Pharmacol 1986;21(1):71-4.
28. Yagupsky P, Gorodischer R. Massive clonidine ingestion with hypertension in a 9 month old infant. Pediatrics 1983;72(4):500-2.
29. North OS, Wieland MJ, Peterson CD, Krenzelok EP. Naloxone administration in clonidine overdosage. Ann Emerg Med 1981;10(7):397.
30. Wiley JF, Wiley CC, Torrey SB, Henretig FM. Clonidine poisoning in young children. J Pediatr 1990;116(4):654-8.
31. Banner W Jr, Lund ME, Clawson L. Failure of naloxone to reverse clonidine toxic effect. Am J Dis Child 1983;137(12):1170-1.
32. Staats P, Whitworth M, Barakat M, Anderson W, Lilienfield S. The use of implanted programmable infusion IDDDs in the management on nonmalignant, chronic low-back pain. Neuromodulation 2007;10(4):376-80.
33. Goucke CR, Dusci LJ, Van Leeuwen S, Fairclough D, Ilett KF. Stability and tolerability of high concentrations of intrathecal bupivacaine and opioid mixtures in chronic non-cancer pain: An open-label pilot study. Pain Med 2010;11(11):1612-8.
34. MIMS Online [database on the Internet]. MIMS Australia; 2011. Available at: (accessed January 2011).
35. Beecroft C, Davies G. Systemic toxic effects of local anaesthetics. Anaesth Intensive Care Med 2010;11(3):98-100.
36. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manage 2009;5(3):521-34.
37. Wallace MS. Ziconotide: A new non-opioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 2006;6(10):1423-8.
38. Leung NY, Whyte IM, Isbister GK. Baclofen overdose: Defining the spectrum of toxicity. Emerg Med Australas 2006;18(1):77-82.
39. Coffey RJ, Edgar TS, Francisco GE, etal. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002;83(6):735-41.